New drug combination targets cancer and senescent cells while extending lifespan in old mice
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Oct-2026 16:17 ET (23-Oct-2026 20:17 GMT/UTC)
VCU Massey Comprehensive Cancer Center was recently awarded a $2.7 million Worta McCaskill-Stevens K12 grant from the National Institutes of Health (NIH). The five-year grant will allow Massey to mentor promising, multidisciplinary, early-stage clinical investigators in the conception, development, and implementation of innovative cancer prevention and control studies designed to optimize participation by cancer survivors and individuals most at risk for cancer throughout Virginia.VCU Massey Comprehensive Cancer Center was recently awarded a $2.7 million Worta McCaskill-Stevens K12 grant from the National Institutes of Health (NIH). The five-year grant will allow Massey to mentor promising, multidisciplinary, early-stage clinical investigators in the conception, development, and implementation of innovative cancer prevention and control studies designed to optimize participation by cancer survivors and individuals most at risk for cancer throughout Virginia.
Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options and poor prognosis. Understanding the molecular drivers of SCLC is essential for developing effective therapies. This study identified FAK splicing variants as a novel feature of SCLC that promote tumor progression and confer therapy resistance. Targeting these variants sensitized SCLC cells to treatment, revealing a promising therapeutic vulnerability. These findings provide new insights into SCLC biology and suggest potential therapeutic strategies for this difficult-to-treat cancer.
Liver cancer often returns after surgery, but doctors currently lack reliable tools to identify which patients face the greatest risk.
Singapore researchers have uncovered two distinct ways that hepatocellular carcinoma, the most common type of liver cancer, recurs at the molecular level and have used these insights to develop a new machine-learning prediction tool.
Validated across independent patient groups, the tool leverages on both genomics and clinical data and outperformed the commonly used TNM staging system – which assesses disease stage based on tumour burden alone – in predicting recurrence risk and could aid surveillance, treatment decision-making and clinical trials.
New research reveals that cells of the same chronological age can follow dramatically different biological aging paths, offering new insights into cancer, neurodegeneration, and the fundamental biology of aging. Rather than aging uniformly, tissues become a mosaic of biologically younger and older cells, with some individual cells aging much faster than others—a discovery that could reshape how scientists understand aging and the earliest origins of age-related disease.
- KAIST and THOR Therapeutics block a key brain signal to prevent muscle loss and extend survival
- Survival rate rose from 20% to 90% even after cachexia had already progressed, prompting the team to propose a next-generation RNA therapeutic strategy
- Preclinical work is underway, with clinical development targeted for 2030, and commercialization efforts to follow
An evidence review of international research suggests widespread misconceptions within the medical community about early milk production, pacifiers and breast pumps may be undermining breastfeeding success in the critical first days after birth.